Table 2.
Demographic data and clinical and laboratory characteristics of the severe and mild MPP groups.
| Mild MPP (n = 569) |
Severe MPP (n = 220) |
P value | |
|---|---|---|---|
| Age, years | 3.32 ± 2.68 | 4.19 ± 2.98 | 0.000 |
| Sex (male/female) | 313/256 | 115/105 | 0.524 |
| Duration of fever before hospitalization, days | 4.23 ± 3.31 | 5.47 ± 4.03 | 0.000 |
| Length of hospitalization, days | 8.16 ± 2.22 | 9.6 ± 3.95 | 0.000 |
| Fever, n (%) | 476 (83.65%) | 191 (86.81) | 0.323 |
| Cough, n (%) | 569 (100%) | 219 (99.5%) | 1.000 |
| Wheezing, n (%) | 160 (28.11%) | 66 (30.00%) | 0.599 |
| WBC × 109/L | 9.71 ± 4.31 | 10.03 ± 5.00 | 0.367 |
| Neutrophils, % | 52.68 ± 16.64 | 58.80 ± 17.59 | 0.000 |
| Lymphocytes, % | 37.75 ± 28.47 | 32.51 ± 16.33 | 0.048 |
| Platelets × 109/L | 275.72 ± 28.47 | 301.59 ± 116.85 | 0.004 |
| LDH, U/L | 382.16 ± 222.91 | 387.81 ± 159.21 | 0.749 |
| CRP, mg/L | 14.59 ± 17.47 | 20.78 ± 27.09 | 0.002 |
| Cell-mediated immunity, % | |||
| CD3+ cells | 64.70 ± 10.39 | 63.82 ± 11.11 | 0.330 |
| CD3 + CD4+ cells | 35.70 ± 9.01 | 35.39 ± 8.99 | 0.682 |
| CD3 + CD8+ cells | 25.80 ± 7.62 | 25.21 ± 8.06 | 0.365 |
| CD3 − CD19+ cells | 19.28 ± 8.63 | 19.18 ± 9.46 | 0.888 |
| CD3 − CD(16+ 56+)+ natural killer cells | 12.01 ± 6.91 | 12.55 ± 7.19 | 0.372 |
| CD4+/CD8+ | 1.52 ± 0.66 | 1.55 ± 0.71 | 0.584 |
| Humoral immunity, g/L | |||
| IgA | 1.07 ± 0.68 | 1.05 ± 0.68 | 0.736 |
| IgG | 7.85 ± 3.39 | 8.56 ± 3.12 | 0.008 |
| IgM | 2.19 ± 2.39 | 1.88 ± 1.93 | 0.084 |
| Log(MP DNA) | 5.10 ± 1.33 | 5.26 ± 1.40 | 0.132 |
MPP, Mycoplasma pneumoniae pneumonia; WBC, white blood cells; LDH, L-lactate dehydrogenase; CRP, C-reactive protein; CD, cluster of differentiation; Ig, immunoglobulin; MP, Mycoplasma pneumoniae. Data are presented as mean ± standard deviation or number (percentage).